MA33091B1 - Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques - Google Patents
Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiquesInfo
- Publication number
- MA33091B1 MA33091B1 MA34134A MA34134A MA33091B1 MA 33091 B1 MA33091 B1 MA 33091B1 MA 34134 A MA34134 A MA 34134A MA 34134 A MA34134 A MA 34134A MA 33091 B1 MA33091 B1 MA 33091B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- rdea119
- bay
- treatment
- specific cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15940309P | 2009-03-11 | 2009-03-11 | |
| PCT/US2010/027060 WO2010105110A1 (en) | 2009-03-11 | 2010-03-11 | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33091B1 true MA33091B1 (fr) | 2012-03-01 |
Family
ID=42135921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34134A MA33091B1 (fr) | 2009-03-11 | 2010-03-11 | Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8673876B2 (https=) |
| EP (1) | EP2405908B1 (https=) |
| JP (2) | JP5767122B2 (https=) |
| KR (1) | KR20110132371A (https=) |
| CN (2) | CN103948600A (https=) |
| AU (1) | AU2010224044A1 (https=) |
| BR (1) | BRPI1009448A2 (https=) |
| CA (2) | CA2972379A1 (https=) |
| CL (1) | CL2011002233A1 (https=) |
| CO (1) | CO6430423A2 (https=) |
| CR (1) | CR20110479A (https=) |
| CU (1) | CU20110170A7 (https=) |
| DO (1) | DOP2011000282A (https=) |
| EA (1) | EA201101302A1 (https=) |
| EC (1) | ECSP11011314A (https=) |
| HK (1) | HK1199710A1 (https=) |
| IL (1) | IL214749A0 (https=) |
| MA (1) | MA33091B1 (https=) |
| MX (1) | MX2011009498A (https=) |
| PE (1) | PE20120105A1 (https=) |
| SG (1) | SG174272A1 (https=) |
| TN (1) | TN2011000455A1 (https=) |
| WO (1) | WO2010105110A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2013001372A2 (en) * | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| EP2788378A4 (en) * | 2011-12-09 | 2015-09-09 | Oncomed Pharm Inc | COMBINATION THERAPY FOR CANCER TREATMENT |
| US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| EP3043778B1 (en) * | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| EP2848246A1 (en) * | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| WO2002039958A2 (en) * | 2000-11-03 | 2002-05-23 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| AU2002340139A1 (en) * | 2001-10-09 | 2003-04-22 | The University Of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| KR20060022647A (ko) * | 2003-04-25 | 2006-03-10 | 길리애드 사이언시즈, 인코포레이티드 | 키나아제 억제 포스포네이트 유사체 |
| WO2006066267A2 (en) * | 2004-12-17 | 2006-06-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| WO2006076463A2 (en) * | 2005-01-12 | 2006-07-20 | Amgen Inc. | Kinase-directed, activity-based probes |
| JP5106098B2 (ja) * | 2005-02-28 | 2012-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の抗癌剤との新規併用 |
| CA2618218C (en) * | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US8329421B2 (en) | 2007-07-13 | 2012-12-11 | Ventana Medical Systems, Inc. | Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein |
| EA032294B1 (ru) | 2007-07-30 | 2019-05-31 | Арди Байосайенсиз, Инк. | Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного |
| CA2924436A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use |
| US8044240B2 (en) * | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| DE102008031039A1 (de) * | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Tarceva zur Anwendung in der Organtransplantation. |
-
2010
- 2010-03-11 WO PCT/US2010/027060 patent/WO2010105110A1/en not_active Ceased
- 2010-03-11 KR KR1020117021234A patent/KR20110132371A/ko not_active Withdrawn
- 2010-03-11 CN CN201310462579.9A patent/CN103948600A/zh active Pending
- 2010-03-11 CN CN2010800209977A patent/CN102421427B/zh not_active Expired - Fee Related
- 2010-03-11 SG SG2011064300A patent/SG174272A1/en unknown
- 2010-03-11 CA CA2972379A patent/CA2972379A1/en not_active Abandoned
- 2010-03-11 EP EP10709139.9A patent/EP2405908B1/en active Active
- 2010-03-11 AU AU2010224044A patent/AU2010224044A1/en not_active Abandoned
- 2010-03-11 US US13/255,278 patent/US8673876B2/en not_active Expired - Fee Related
- 2010-03-11 JP JP2011554220A patent/JP5767122B2/ja not_active Expired - Fee Related
- 2010-03-11 EA EA201101302A patent/EA201101302A1/ru unknown
- 2010-03-11 BR BRPI1009448A patent/BRPI1009448A2/pt not_active IP Right Cessation
- 2010-03-11 PE PE2011001622A patent/PE20120105A1/es not_active Application Discontinuation
- 2010-03-11 MA MA34134A patent/MA33091B1/fr unknown
- 2010-03-11 CA CA2754913A patent/CA2754913C/en not_active Expired - Fee Related
- 2010-03-11 MX MX2011009498A patent/MX2011009498A/es not_active Application Discontinuation
-
2011
- 2011-08-18 IL IL214749A patent/IL214749A0/en unknown
- 2011-09-09 DO DO2011000282A patent/DOP2011000282A/es unknown
- 2011-09-09 CO CO11116967A patent/CO6430423A2/es not_active Application Discontinuation
- 2011-09-09 TN TN2011000455A patent/TN2011000455A1/fr unknown
- 2011-09-09 CL CL2011002233A patent/CL2011002233A1/es unknown
- 2011-09-09 EC EC2011011314A patent/ECSP11011314A/es unknown
- 2011-09-09 CR CR20110479A patent/CR20110479A/es unknown
- 2011-09-09 CU CU20110170A patent/CU20110170A7/es unknown
-
2013
- 2013-11-18 US US14/082,681 patent/US9220696B2/en not_active Expired - Fee Related
-
2014
- 2014-09-04 JP JP2014180216A patent/JP5911929B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-08 HK HK15100195.6A patent/HK1199710A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33091B1 (fr) | Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
| MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
| WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
| WO2007081680A3 (en) | Microrna expression abnormalities in pancreatic endocrine and acinar tumors | |
| MA33469B1 (fr) | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| WO2007033023A3 (en) | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| WO2007062138A3 (en) | Methods and compositions for treating diseases targeting human prominin-1(cd133) | |
| WO2012058241A3 (en) | Methods and compositions for ameliorating pancreatic cancer | |
| MX336761B (es) | Compuestos para el tratamiento de cancer. | |
| WO2008115750A3 (en) | Compositions and methods for the treatment of cancer | |
| NZ603952A (en) | Phosphaplatins and their use for treatment of cancers | |
| PH12018500003A1 (en) | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma | |
| MX2009010271A (es) | Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana. | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
| EP4286853A3 (en) | Compositions for ovarian cancer assessment having improved specificity | |
| WO2013081645A3 (en) | Erbb3 mutations in cancer | |
| WO2010026473A3 (en) | Pta072 protein | |
| EP2099458A4 (en) | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR PRESENTATION AND THERAPY | |
| IN2014KN00796A (https=) |